亚裔转移性前列腺癌患者接受外照射放疗比其他种族/族裔的患者有生存优势。
Survival advantage of Asian metastatic prostate cancer patients treated with external beam radiotherapy over other races/ethnicities.
机构信息
Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Martinistraße 52, 20246, Hamburg, Germany.
Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, QC, Canada.
出版信息
World J Urol. 2021 Oct;39(10):3781-3787. doi: 10.1007/s00345-021-03720-7. Epub 2021 May 12.
PURPOSE
To assess the effect of race/ethnicity in cancer-specific mortality (CSM) adjusted for other-cause mortality (OCM) in metastatic prostate cancer patients (mPCa) treated with external beam radiotherapy (EBRT) to the prostate.
METHODS
We relied on the Surveillance, Epidemiology, and End Results (SEER) database to identify Caucasian, African-American, Hispanic/Latino and Asian mPCa patients treated by EBRT between 2004 and 2016. Cumulative incidence plots displayed CSM after adjustment for OCM according to race/ethnicity. Propensity score matching accounted for patient age, prostate-specific antigen, clinical T and N stages, Gleason Grade Groups and M1 substages. OCM adjusted multivariable analyses tested for differences in CSM in African-Americans, Hispanic/Latinos and Asians relative to Cauacasians.
RESULTS
After 3:1 propensity score matching and OCM adjustment, Asians exhibited lower CSM at 60 and 120 months (48.2 and 60.0%, respectively) compared to Caucasians (66.7 and 79.4%, respectively, p < 0.001). In OCM adjusted multivariable analyses, Asian race/ethnicity was associated with lower CSM (HR 0.66, CI 0.52-0.83, p < 0.001). Conversely, African-American and Hispanic/Latino race/ethnicity did not affect CSM. OCM rates were comparable between examined races/ethnicities.
CONCLUSION
In the setting of mPCa treated with EBRT, Asians exhibit lower CSM than Caucasians, African-Americans and Hispanic/Latinos. This observation may warrant consideration in prognostic stratification schemes for newly diagnosed mPCa patients.
目的
评估种族/民族在接受前列腺外照射放疗(EBRT)治疗的转移性前列腺癌(mPCa)患者中,经其他原因死亡率(OCM)调整后的癌症特异性死亡率(CSM)的影响。
方法
我们依赖监测、流行病学和最终结果(SEER)数据库,确定了 2004 年至 2016 年间接受 EBRT 治疗的白种人、非裔美国人、西班牙裔/拉丁裔和亚洲 mPCa 患者。根据种族/民族,在调整 OCM 后,累积发病率图显示了 CSM。倾向评分匹配考虑了患者年龄、前列腺特异性抗原、临床 T 和 N 期、Gleason 分级组和 M1 亚期。OCM 调整的多变量分析测试了非裔美国人、西班牙裔/拉丁裔和亚洲人相对于白种人在 CSM 方面的差异。
结果
经过 3:1 的倾向评分匹配和 OCM 调整后,亚洲人在 60 个月和 120 个月时的 CSM 较低(分别为 48.2%和 60.0%,p<0.001)。在 OCM 调整的多变量分析中,亚洲种族/民族与较低的 CSM 相关(HR 0.66,CI 0.52-0.83,p<0.001)。相反,非裔美国人和西班牙裔/拉丁裔种族/民族并不影响 CSM。在研究的种族/民族之间,OCM 率相当。
结论
在接受 EBRT 治疗的 mPCa 中,亚洲人的 CSM 低于白种人、非裔美国人和西班牙裔/拉丁裔。这一观察结果可能需要在新诊断的 mPCa 患者的预后分层方案中加以考虑。
相似文献
Int Urol Nephrol. 2022-7
引用本文的文献
Prostate Cancer Prostatic Dis. 2023-9
本文引用的文献
Prostate Cancer Prostatic Dis. 2021-3
N Engl J Med. 2019-6-2
N Engl J Med. 2019-5-31
Prostate Int. 2019-3
Prostate Cancer Prostatic Dis. 2018-10-2
Curr Urol Rep. 2017-8-14